Consumer groups ask FTC to block Novo Holdings-Catalent deal
Consumer groups and unions express competition concerns to FTC
Deal could limit options for competitors developing GLP-1 drugs
Concerns also raised about impact on gene therapy manufacturing
Updates Oct. 17 story with Novo Holdings declining comment, paragraph 7
By Jody Godoy and Maggie Fick
NEW YORK, Oct 18 (Reuters) -U.S. consumer groups and two large labor unions urged the U.S. Federal Trade Commission on Thursday to block Novo Holdings, the controlling shareholder of Novo Nordisk NOVOb.CO, from acquiring contract drug manufacturer Catalent CTLT.N, saying the deal threatens competition in weight loss drugs and cutting-edge gene therapies.
U.S. Public Interest Research Group, Service Employees International Union (SEIU) and others expressed concerns in a letter to the FTC about the $16.5 billion deal, which Novo Holdings has said would boost supply of Wegovy, Novo's blockbuster GLP-1 injectable weight-loss drug.
Last week, U.S. Senator Elizabeth Warren, a Democrat, called on the FTC to look closely at the deal over similar concerns.
The deal could constrain options for competitors such as Amgen AMGN.O, Pfizer PFE.N, Roche ROG.S, and AstraZeneca AZN.L, who are reportedly developing their own GLP-1 drugs, the groups said.
"Because of the proposed acquisition, there is a real question of whether these future rivals to Novo will be able to secure the expertise to bring the product to market and have available and qualified capacity to manufacture these products when they commercially launch," the groups said.
Viking Therapeutics VKTX.O, Structure Therapeutics GPCR.O and Sun Pharma SUN.NS also have GLP-1 drugs in development and could be affected, the groups said.
ANovo Holdings spokesperson declined to comment.
A Viking spokesperson declined to comment. The other companies did not immediately respond to requests for comment on Thursday.
According to the terms of the deal, Novo Holdings would sell three of Catalent's factories, where injection pens are filled in sterile conditions, in Italy, Belgium and the United States, on to Novo Nordisk for $11 billion.
Novo Nordisk has said it is committed to honoring existing contracts at the plants, and that it is not aware of any competitive GLP-1 products being manufactured for commercial sale at the three sites.
The groups, which included Consumer Action, diabetes group Beta Cell Action, Doctors for America and the American Federation of State, County and Municipal Employees (AFSCME) union, also expressed concern that Novo Holding's ownership could affect Catalent's capacity to manufacture gene therapies.
AFSCME represents around 1.6 million public sector workers, and SEIU has around 2 million members who work in healthcare, the public sector and property services.
Ten consumer groups had signed on to the letter on Thursday afternoon.
"The competitive concerns here go far beyond existing drugs. We believe the commission should look at the impact on future therapies including gene therapy," said David Balto, the antitrust lawyer who represents the groups and drafted the letter.
The letter mentioned Catalent's contracts with Sarepta Therapeutics SRPT.O, to produce its gene therapy Elevidys, and with Novartis NOVN.S, to produce its gene therapy Zolgensma. The Catalent facilities involved are separate from the three factories that Novo Holdings plans to sell on to Novo Nordisk.
Sarepta does do not anticipate any impact from the Catalent acquisition, spokesperson Tracy Sorrentino said on Thursday. Sarepta's contract with Catalent runs through 2028.
A Novartis spokesperson said on Thursday that Zolgensma is no longer manufactured at any Catalent facility.
Reporting by Jody Godoy in New York and Maggie Fick in London; Editing by Nick Zieminski and Sonali Paul
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
